Investigating a vaccine's ability to control SIV infection in monkeys
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy
This study is testing a new vaccine for monkeys that helps their immune systems fight off a virus similar to HIV, with the hope that it will lead to better ways to prevent and treat HIV in people.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10895461 on NIH RePORTER |
What this research studies
This research focuses on a vaccine that uses Rhesus Cytomegalovirus to express parts of the simian immunodeficiency virus (SIV) to stimulate the immune system in monkeys. The goal is to understand how specific immune responses, particularly from CD8+ T cells, can effectively control and potentially clear SIV infections. By identifying the minimal viral components needed to trigger these immune responses, the research aims to enhance the vaccine's effectiveness in preventing viral replication. This could lead to significant advancements in how we approach SIV and potentially HIV in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are non-human primates, particularly Rhesus monkeys, that are susceptible to SIV infection.
Not a fit: Patients who are not non-human primates or those who do not have SIV will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce or eliminate SIV infections, which may have implications for HIV treatment in humans.
How similar studies have performed: Previous research has shown promise in using similar vaccine strategies to control viral infections, indicating potential for success in this approach.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Picker, Louis J. — Oregon Health & Science University
- Study coordinator: Picker, Louis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.